Defining DNA Damage Response (DDR)-based therapeutics in cancer
We are pioneering breakthroughs and innovations in DDR-based treatments to address a broad spectrum of difficult-to-treat cancers.
Unparalleled Experience in DDR
At Artios, we converge decades of experience from unparalleled DDR insights encapsulating multiple pathways to create breakthrough cancer medicines.
Our CEO Niall Martin, PhD, and CSO Graeme Smith, PhD, are industry-leading experts having pioneered the field through the invention of the blockbuster PARP inhibitor (now marketed as Lynparza (olaparib) by AstraZeneca) and several successful DDR-based programs.
Our team of DDR innovators is leveraging our expertise to fill an industry-leading pipeline.
Our Approach
Our comprehensive anti-cancer approach exploits the full range of DDR-based therapeutic opportunities beyond synthetic lethality, expanding our potential to develop drugs with a variety of applications. Based on insights into a cell’s ensemble of DDR pathways, we are advancing a pipeline of product candidates with first- and best-in-class potential. Our goal is to be the foremost DDR-focused biotechnology company, with clear paths to driving transformative clinical results and achieving lasting patient benefits.
Our Mission
We are committed to developing new classes of DDR drugs that achieve an unreached level of therapeutic impact for patients with hard-to-treat solid tumors.
Our Pipeline
ART0380, our selective inhibitor of ataxia telangiectasia and Rad3-related protein (ATR) with best-in-class potential can induce DNA damage in sensitive cancer tissue with limited effect on DNA integrity in healthy tissue. ART0380 is being evaluated in clinical trials as an oral anti-cancer agent targeting replication stress and removing a cancer cell’s remaining mechanism for survival. Our clinical data supports a defined path to a pivotal trial and market entry.
Learn moreART6043 is the most advanced clinical Polθ program in the industry. It is a selective, orally bioavailable, small-molecule inhibitor of the polymerase domain of DNA polymerase theta (Polθ), a DNA repair enzyme that is expressed in cancer cells but is virtually absent in most healthy tissues.
ART6043 has broad potential as a combination treatment across multiple tumor types and is currently being evaluated in clinical trials in combination with olaparib.
Learn moreOur wholly-owned ALT program targets a DDR driven process called Alternative Lengthening of Telomeres (ALT). This process occurs at chromosome ends, called telomeres, enabling cancer cells to maintain their replicative immortality. We are exploring multiple potential ALT targets within disease contexts representing significant unmet medical needs.
Learn moreOur proprietary platform, DcoDeR, is a specialized approach that harnesses the intricate biology of the DDR to unlock its potential and drive groundbreaking clinical development strategies through optimal drug combinations, specific biomarker-driven insights, disease positioning, and patient stratification.
Learn more
